Non-Vitamin K Oral Anticoagulants (NOACs) and Their Reversal
AbstractPurpose of ReviewAn 80-year-old man presents with an acute right hemiparesis and National Institutes of Health Stroke Scale (NIHSS) of 25, 14 h after taking dabigatran. Activated partial thromboplastin time (aPTT) is 42.8 s. Arteriogram demonstrates left internal carotid artery thrombosis. What is the appropriate management of this patient with acute ischemic stroke while on a NOAC?Recent FindingsIdarucizumab is a reversal agent approved for dabigatran, and two more reversal agents, andexanet alfa and aripazine, are currently in development for NOACs.SummaryIn this article, we review currently available NOACs, their laboratory monitoring, and reversal agents.
Source: Current Neurology and Neuroscience Reports - Category: Neuroscience Source Type: research
More News: Brain | Ischemic Stroke | Laboratory Medicine | National Institutes of Health (NIH) | Neurology | Neuroscience | Pradaxa | Stroke | Thrombosis | Vitamin K | Vitamins